Reno, Nevada – Conexeu Sciences Inc. (“Conexeu” or the “Company”), a pre-commercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as President & Chief Executive Officer of the Company. He has also been appointed to the Company’s Board of Directors.
At Conexeu, Miles will lead the Company’s next phase of growth, advancing its first-in-class collagen platform for human and animal health. He intends to focus on scientific validation, strategic partnerships, and a unified brand strategy across wound care, dental, and aesthetics.
“Miles brings a rare combination of proven leadership, commercial discipline, market insight, and deep respect for science,” said Jeff Sharpe, Chairman of the Board of Conexeu Sciences Inc. “He has a long history of building high-performance organizations and creating shareholder value, whilst leading teams that consistently outpace the market. His vision positions Conexeu to shape the future of human and animal regenerative medicine.”
Dr. Claudia Chavez-Munoz, Co-Founder and Chief Science Officer of the Company, added: “True tissue regeneration means complete structural and functional restoration of native tissue. Our CXU™ platform represents a next-generation liquid extracellular matrix, which provides a complex and bioactive scaffold that mimics the native extracellular matrix architecture, offering cells the biological signals required for organized healing, not scarring. We are delighted to welcome Miles at this pivotal stage; his proven ability to translate scientific innovation into global commercial success will be instrumental in advancing Conexeu’s mission.”
Miles brings more than two decades of leadership in scaling category-defining healthcare and aesthetics businesses. At Galderma, he served as President and CEO, North America, delivering sustained growth across Restylane®, Sculptra®, Dysport®, Cetaphil®, Differin®, and Epiduo®, while managing one of the most dynamic portfolios in dermatology. As Co-Founder and CEO of Novaestiq Corp., he built a differentiated aesthetics company from inception to acquisition by Waldencast plc (NASDAQ: WALD) in just four years. Since 2020, Miles has also served on the Board of Castle Biosciences, Inc. (NASDAQ: CSTL).
“Conexeu represents the next frontier,” said Miles Harrison. “Our CXU™ collagen platform is positioned as the foundation for regenerative innovation, patented across multiple markets; we are not following trends; we are building a company that we believe will define the future of restoration and renewal and deliver life-changing solutions and a better quality of life to patients and consumers worldwide.”
Read Original Release: https://www.newsfilecorp.com/release/272786/Conexeu-Sciences-Appoints-Miles-Harrison-as-President-Chief-Executive-Officer-to-Shape-the-Future-of-True-Tissue-Regeneration
